EMBRACE - From Vulnerable to Empowered: Implementation and Evaluation of a Multicomponent Program to Tackling Age-related Decline
NCT07628686, Not applicable, Not yet recruiting, University Fernando Pessoa
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | EMBRACE - From Vulnerable to Empowered: Implementation and Evaluation of a Multicomponent Program to Tackling Age-related Decline | ClinicalTrials.gov |
| NCT number | NCT07628686 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University Fernando Pessoa | ClinicalTrials.gov |
| Conditions | Age-Related Cognitive Decline | ClinicalTrials.gov |
| Interventions | EMBRACE Intervention | ClinicalTrials.gov |
| First posted | 2026-06-05 | ClinicalTrials.gov |
| Last updated | 2026-06-05 | ClinicalTrials.gov |
Registered outcomes 28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Montreal Cognitive Assessment (MoCA) | Baseline, post-intervention (12 months), and 6-month follow-up. | General cognitive functions will be assessed using the MoCA. The MoCA is a cognitive screening instrument used to evaluate multiple cognitive domains, with scores ranging from 0 to 30, where higher scores indicate better cognitive performance. | ClinicalTrials.gov |
| Primary | World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) | Baseline, post-intervention (12 months), and 6-month follow-up. | Quality of life will be assessed using the WHOQOL-BREF. The WHOQOL-BREF is a questionnaire used to evaluate quality of life across physical, psychological, social relationships, and environmental domains, with scores ranging from 0 to 100, where higher scores indicate better quality of life. | ClinicalTrials.gov |
| Secondary | d2 Test | Baseline, post-intervention (12 months), and 6-month follow-up. | Selective attention and concentration ability will be assessed using the d2 Test. The d2 Test is a neuropsychological instrument used to evaluate selective attention, concentration, and processing speed through a timed cancellation task consisting of 14 lines to be completed in a maximum of 20 seconds per line. Performance is measured through task execution indices, concentration, processing speed, and error percentage. Higher scores on task execution and concentration indices, and lower error percentages, indicate better attentional performance. | ClinicalTrials.gov |
| Secondary | INECO Frontal Screening (IFS) | Baseline, post-intervention (12 months), and 6-month follow-up. | Executive functions will be assessed using the IFS. The IFS is a cognitive screening instrument used to evaluate executive functioning, including inhibitory control, cognitive flexibility, working memory, and abstraction ability, with scores ranging from 0 to 30, where higher scores indicate better executive functioning. | ClinicalTrials.gov |
| Secondary | Stroop Test | Baseline, post-intervention (12 months), and 6-month follow-up. | Inhibitory control, cognitive flexibility, and resistance to interference will be assessed using the Stroop Test. The Stroop Test consists of three tasks (word, color, and color-word), each administered within a maximum time of 45 seconds. Performance is measured by the number of words, colors, and stimuli correctly identified, where higher scores indicate better cognitive performance. | ClinicalTrials.gov |
| Secondary | Trail Making Test (TMT) | Baseline, post-intervention (12 months), and 6-month follow-up. | Alternating attention, visual attention, and processing speed will be assessed using the TMT. The TMT is a neuropsychological instrument used to evaluate visual attention, alternating attention, and processing speed through a timed task requiring participants to connect a sequence of numbers and letters. Performance is measured by completion time in seconds, where shorter completion times indicate better cognitive performance. | ClinicalTrials.gov |
| Secondary | Spatial Span Subtest of the Wechsler Memory Scale - Third Edition (WMS-III) | Baseline, post-intervention (12 months), and 6-month follow-up. | Working memory will be assessed using the Spatial Span Subtest of the WMS-III. The Spatial Span Subtest is a neuropsychological instrument used to evaluate visuospatial working memory through forward and backward span tasks, with scores ranging from 0 to 32, where higher scores indicate better working memory performance. | ClinicalTrials.gov |
| Secondary | Logical Memory Subtest of the Wechsler Memory Scale - Third Edition (WMS-III) | Baseline, post-intervention (12 months), and 6-month follow-up. | Immediate and delayed verbal episodic memory will be assessed using the Logical Memory Subtest of the WMS-III. The Logical Memory Subtest is a neuropsychological instrument used to evaluate the recall and recognition of verbally presented information, with scores ranging from 0 to 75 for immediate recall, 0 to 30 for delayed recall, and 0 to 30 for recognition, where higher scores indicate better memory performance. | ClinicalTrials.gov |
| Secondary | Rey Auditory Verbal Learning Test (RAVLT) | Baseline, post-intervention (12 months), and 6-month follow-up. | Verbal learning and memory will be assessed using the RAVLT. The RAVLT is a neuropsychological instrument used to evaluate verbal learning, immediate recall, delayed recall, and recognition memory through repeated presentation of a 15-word list. Performance is measured by the number of correctly recalled or recognized words across the assessment trials, where higher scores indicate better verbal learning and memory performance. | ClinicalTrials.gov |
| Secondary | Boston Naming Test (BNT) | Baseline, post-intervention (12 months), and 6-month follow-up. | Naming ability will be assessed using the BNT. The BNT is a neuropsychological instrument used to evaluate confrontation naming ability through the identification of visually presented objects, with scores ranging from 0 to 60, where higher scores indicate better naming performance. | ClinicalTrials.gov |
| Secondary | Phonemic and Semantic Verbal Fluency Tests | Baseline, post-intervention (12 months), and 6-month follow-up. | Verbal fluency and executive functions will be assessed through Phonemic and Semantic Verbal Fluency Tests. These neuropsychological tests are used to evaluate information retrieval from memory, executive functions (such as cognitive flexibility, planning, and inhibitory control), and language production through word generation within a maximum time frame of 1 minute for each task, where higher scores indicate better performance in verbal fluency. | ClinicalTrials.gov |
| Secondary | Instrumental Activities of Daily Living (IADL) | Baseline, post-intervention (12 months), and 6-month follow-up. | Functionality in instrumental activities of daily living will be assessed using the IADL scale. The IADL scale is used to evaluate independence in everyday functional activities, with scores ranging from 8 to 31, where lower scores indicate greater functional independence. | ClinicalTrials.gov |
| Secondary | Hospital Anxiety and Depression Scale (HADS) | Baseline, post-intervention (12 months), and 6-month follow-up. | Symptoms of anxiety and depression will be assessed using the HADS. The HADS is a self-report questionnaire used to evaluate symptoms of anxiety and depression, with scores ranging from 0 to 21 for each subscale, where higher scores indicate greater symptom severity. | ClinicalTrials.gov |
| Secondary | Numerical Activities of Daily Living - Financial (NADL-F) | Baseline, post-intervention (12 months), and 6-month follow-up. | Financial literacy and functionality in numerical activities of daily living will be assessed using the NADL-F assessment. The NADL-F is used to evaluate financial abilities and numerical functioning in everyday activities across domains including money counting (scores ranging from 0 to 5), reading abilities (0 to 8), purchasing articles (0 to 14), percentages (0 to 9), financial concepts (0 to 14), bill payment (0 to 6), and financial judgment (0 to 6), where higher scores indicate better financial functioning and autonomy in daily life. | ClinicalTrials.gov |
| Secondary | Bedside Language Test | Baseline, post-intervention (12 months), and 6-month follow-up. | Language abilities will be assessed using the Bedside Language Test. The Bedside Language Test is a language assessment tool used to evaluate speech, language comprehension, repetition, reading, and writing abilities, with scores ranging from 0 to 25, where higher scores indicate better language performance. | ClinicalTrials.gov |
| Secondary | PREDIMED | Baseline, post-intervention (12 months), and 6-month follow-up. | Adherence to the Mediterranean diet will be assessed using the PREDIMED questionnaire. The PREDIMED questionnaire is used to evaluate adherence to Mediterranean dietary patterns, with scores ranging from 0 to 14, where higher scores indicate greater adherence to the Mediterranean diet. | ClinicalTrials.gov |
| Secondary | International Physical Activity Questionnaire (IPAQ) | Baseline, post-intervention (12 months), and 6-month follow-up. | Physical activity level will be assessed using the IPAQ. The IPAQ is used to evaluate the frequency, duration, and intensity of physical activity performed in daily life. Physical activity levels are calculated in MET-minutes per week based on the frequency and duration of walking and moderate- and vigorous-intensity activities, with higher scores indicating higher levels of physical activity. | ClinicalTrials.gov |
| Secondary | Timed Up and Go Test (TUG) | Baseline, post-intervention (12 months), and 6-month follow-up. | Functional mobility and dynamic balance ability will be assessed using the TUG. The TUG is used to evaluate functional mobility and dynamic balance through the time required to stand up from a chair, walk a short distance, return, and sit down, with performance measured in seconds, where shorter completion times indicate better functional mobility and balance. | ClinicalTrials.gov |
| Secondary | Blood Pressure | Baseline, post-intervention (12 months), and 6-month follow-up | Systolic and diastolic blood pressure will be measured in millimeters of mercury (mmHg). Scores range from approximately (for diastolic) 60-120 and (for systolic) 100-180 mmHg, with higher scores indicating higher blood pressure. | ClinicalTrials.gov |
| Secondary | Body Mass Index (BMI) | Baseline, post-intervention (12 months), and 6-month follow-up | Body mass index (BMI) will be calculated using body weight and height and expressed in kilograms per square meter (kg/m²). BMI is a measure of body size based on weight relative to height. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 24
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 12661673 | RESULT | PubMed |
| 14590636 | RESULT | PubMed |
| 15147597 | RESULT | PubMed |
| 16914401 | RESULT | PubMed |
| 17365902 | RESULT | PubMed |
| 19276547 | RESULT | PubMed |
| 20223924 | RESULT | PubMed |
| 21767731 | RESULT | PubMed |
| 23299183 | RESULT | PubMed |
| 23341434 | RESULT | PubMed |
| 23806438 | RESULT | PubMed |
| 25030513 | RESULT | PubMed |
| 25405755 | RESULT | PubMed |
| 25771249 | RESULT | PubMed |
| 25940230 | RESULT | PubMed |
| 26044346 | RESULT | PubMed |
| 26707544 | RESULT | PubMed |
| 28912076 | RESULT | PubMed |
| 29407466 | RESULT | PubMed |
| 30561718 | RESULT | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 8
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Cancellation Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Short Story Recall | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)